Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Claussen

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Plos One|December 3, 2015
Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial PneumoniasMarius M Hoeper, Juergen Behr, Matthias Held, et al.
The European Respiratory Journal|May 9, 2020
Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registryJürgen Behr, Antje Prasse, Hubert Wirtz, et al.
Respiratory Research|March 17, 2019
The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registryMichael Kreuter, Jeff Swigris, David Pittrow, et al.
Nature|March 26, 2026
Decadal-scale droughts disrupted the African Humid Period in the SaharaFlorence Sylvestre, Martin Melles, Volker Wennrich, et al.
Respiratory Research|July 16, 2017
Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registryMichael Kreuter, Jeff Swigris, David Pittrow, et al.
The Lancet. Respiratory Medicine|April 2, 2021
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trialJürgen Behr, Antje Prasse, Michael Kreuter, et al.
The European Respiratory Journal|April 4, 2015
Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registryJürgen Behr, Michael Kreuter, Marius M Hoeper, et al.
Chest|February 13, 2021
Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)Carmine Dario Vizza, Marius M Hoeper, Doerte Huscher, et al.
Circulation|October 2, 2013
Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)Karen M Olsson, Marion Delcroix, H Ardeschir Ghofrani, et al.
ERJ Open Research|January 21, 2026
Risk stratification as a guide to goal-oriented management of patients with fibrotic interstitial lung disease: a registry-based analysisJürgen Behr, Antje Prasse, Hubert Wirtz, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Plos One|December 3, 2015
Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial PneumoniasMarius M Hoeper, Juergen Behr, Matthias Held, et al.
The European Respiratory Journal|May 9, 2020
Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registryJürgen Behr, Antje Prasse, Hubert Wirtz, et al.
Respiratory Research|March 17, 2019
The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registryMichael Kreuter, Jeff Swigris, David Pittrow, et al.
Nature|March 26, 2026
Decadal-scale droughts disrupted the African Humid Period in the SaharaFlorence Sylvestre, Martin Melles, Volker Wennrich, et al.
Respiratory Research|July 16, 2017
Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registryMichael Kreuter, Jeff Swigris, David Pittrow, et al.
The Lancet. Respiratory Medicine|April 2, 2021
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trialJürgen Behr, Antje Prasse, Michael Kreuter, et al.
The European Respiratory Journal|April 4, 2015
Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registryJürgen Behr, Michael Kreuter, Marius M Hoeper, et al.
Chest|February 13, 2021
Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)Carmine Dario Vizza, Marius M Hoeper, Doerte Huscher, et al.
Circulation|October 2, 2013
Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)Karen M Olsson, Marion Delcroix, H Ardeschir Ghofrani, et al.
ERJ Open Research|January 21, 2026
Risk stratification as a guide to goal-oriented management of patients with fibrotic interstitial lung disease: a registry-based analysisJürgen Behr, Antje Prasse, Hubert Wirtz, et al.
Pageof 5